Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company
Retrieved on:
Wednesday, October 20, 2021
Health, Medical Devices, Consumer, Clinical Trials, Men, Research, Science, Safety, Woman, MD, Biotechnology, Quality of life, Entrepreneurship, Hospital, Condom, Knowledge, Ethics, Founders Fund, NIH, Human, Patient, Birth, University of Utah School of Medicine, Acting, MBX, Vasectomy, Infertility, University, Clinical trial, Man, Public health, ADAM, IOS, Male, Health, Fertility, Female, Sexual dysfunction, Doctor of Philosophy, Jaffray Woodriff, Genetics, Financial services, Birth control, Contraline, MBX Capital, CONTRALINE, MBX CAPITAL
Contraline, Inc ., a venture-backed medical device company devoted to providing men and couples with long-lasting, safe, and effective male contraception, has closed $10.7 million in its Series A financing.
Key Points:
- Contraline, Inc ., a venture-backed medical device company devoted to providing men and couples with long-lasting, safe, and effective male contraception, has closed $10.7 million in its Series A financing.
- The financing round was led by MBX Capital, a venture capital firm that invests in early-stage healthcare and life sciences companies.
- Contraline has received ethics approval from the Human Research Ethics Committee based in Melbourne, Australia to conduct the study.
- Contraline, Inc. is a venture-backed medical device company devoted to providing men and couples with long-lasting, safe, and effective contraception.